Threshold Pharmaceuticals: Clinical Trials

9 trials sponsored by Threshold Pharmaceuticals, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 1 unknown. 9 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 5, Terminated 3, Unknown 1
Phase 13Completed 2, Unknown 1

Follow Threshold Pharmaceuticals: new trials by email

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
TH-302 + Sunitinib - Neuroendocrine Tumors, Pancreatic Neoplasms
Phase 2CompletedGrupo Espanol de Tumores Neuroendocrinos172015-05-112020-07-27
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
TH-302 monotherapy - Biliary Tract Cancer
Phase 2CompletedSeoul National University Hospital242015-04-012018-09-10
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
TH-302, Doxorubicin - Soft Tissue Sarcoma
Phase 2TerminatedMerck KGaA, Darmstadt, Germany62014-12-102018-12-14
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib - Multiple Myeloma
Phase 1 / Phase 2UnknownThreshold Pharmaceuticals982012-02-012016-06-02
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
TH-302 - Non-Small Cell Lung Cancer, Prostate Cancer
Phase 1 / Phase 2CompletedThreshold Pharmaceuticals712008-08-012015-05-07
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Glufosfamide - Soft Tissue Sarcoma
Phase 2CompletedEleison Pharmaceuticals LLC.222007-03-012015-03-25
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Glufosfamide - Carcinoma, Small Cell Lung
Phase 2TerminatedThreshold Pharmaceuticals502007-02-012009-04-30
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Lonidamine - Benign Prostatic Hyperplasia
Phase 2TerminatedThreshold Pharmaceuticals2402005-06-012009-04-29
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Glufosfamide, Gemcitabine - Neoplasms, Pancreatic Neoplasms
Phase 1 / Phase 2CompletedThreshold Pharmaceuticals472004-12-012009-04-30

Conditions studied

Pancreatic Neoplasms (3)  ·  Hypoxia (2)  ·  Sarcoma (2)  ·  Biliary Tract Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Multiple Myeloma (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Neoplasms, Plasma Cell (1)  ·  Neuroectodermal Tumors, Primitive (1)  ·  Neuroendocrine Tumors (1)  ·  Prostatic Hyperplasia (1)  ·  Prostatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Interventions

TH 302 (4)  ·  beta-D-glucosylisophosphoramide mustard (3)  ·  Bortezomib (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  Gemcitabine (1)  ·  Sunitinib (1)  ·  lonidamine (1)  ·  pomalidomide (1)

Countries

United States (6)  ·  Brazil (1)  ·  Japan (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Claire Verschraegen, MD (1)  ·  David Mendelson, MD (1)  ·  Do-Youn Oh, MD, PhD (1)  ·  Douglas Adkins, MD (1)  ·  Enrique Grande, MD (1)  ·  Gerald Rosen, MD (1)  ·  Gerold Bepler, MD, PhD (1)  ·  Gina D'Amato, MD (1)  ·  Jeffrey R Infante, MD (1)  ·  John C Ruckdeschel, MD (1)  ·  Kristen Ganjoo, MD (1)  ·  Lee Cranmer, MD, PhD (1)  ·  Mitesh Borad, MD (1)  ·  Peter D Eisenberg, MD (1)

Results publications

PMID 25512461, PMID 34190375

NIH funding

2014 (1)